Navigation Links
Catabasis Closes $32.4 Million Series B Financing
Date:11/14/2013

CAMBRIDGE, Mass., Nov. 15, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced it has completed a $32.4 million Series B financing round led by new investor Lightstone Ventures. A leading public crossover fund and all current Catabasis investors, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures, also participated in the financing.

"This investment reflects our confidence in Catabasis' pipeline of SMART Linker conjugates as much as our belief in management's ability to successfully advance its clinical candidates," said Jean George, partner of Lightstone Ventures. "Catabasis has achieved a number of important milestones in the past year including positive data from Phase 1 studies of both CAT-2003 and CAT-1004. We look forward to working with the management team as they complete the ongoing Phase 2 trial for CAT-2003 and seek to advance the rest of the pipeline."

Catabasis plans to use proceeds from this financing to support the development of its lead compound, CAT-2003, a modulator of the lipid synthesis pathway, which is currently in a Phase 2 clinical trial in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. Catabasis also plans to use the proceeds to support the continued clinical and pre-clinical development of other SMART Linker conjugates in the pipeline.

"We are tremendously excited about the progress we've made with our pipeline thus far, having reported positive Phase 1 data for both CAT-2003 and CAT-1004 and having advanced CAT-2003 to Phase 2," said Jill Milne, Ph.D., co-founder and chief executive officer of Catabasis. "This financing enables Catabasis to continue to execute on the promise of its pipeline for dyslipidemias and diseases involving chronic inflammation." 

About CatabasisCatabasis is a clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profile. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.

Please visit www.catabasis.com for more information.Media Contacts

Corporate ContactTony Russo, Ph.D.

Amy LynchMatt Middleman, M.D.

Catabasis Pharmaceuticals, Inc.Russo Partners

T: (617)-349-1971T: 212-845-4251

alynch@catabasis.comT: 212-845-4272tony.russo@russopartnersllc.commatt.middleman@russopartnersllc.com
'/>"/>

SOURCE Catabasis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
2. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
3. Catabasis Names Ian Sanderson Chief Financial Officer
4. Independa Closes Convertible Note Funding at $2.35 Million
5. Stereotaxis Closes $18.5 Million Private Placement Financings
6. Boston Scientific Closes Cameron Health Acquisition
7. C8 MediSensors Closes $19 million Preferred Stock Financing
8. Igenica Closes $33 Million in Series C Funding
9. BONESUPPORT Closes Second Tranche of Funding
10. PTC Therapeutics Closes $30 Million Financing
11. Chiasma Closes $38.5 Million Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
(Date:4/28/2016)... 28, 2016 Treato , ... healthcare, announced today that it has been named a ... Vendor in Life Sciences, 2016, Stephen Davies ... report focuses on life-science- oriented analytics, algorithms and smart ... and doctors, confirm medication ingestion, and analyze unstructured information. ...
Breaking Medicine Technology:
(Date:4/29/2016)... Newport Beach, Calif. (PRWEB) , ... April 29, 2016 , ... ... affect us. An effective way to confront and deal with these stressors is to ... taste bad to be good for you. Risa Groux, a certified Holistic Nutritionist and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... more flexibility in repaying their loans, more information about their loan terms and ... total outstanding student loan debt, including federal and private loans, has reached $1.3 ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Spine Team ... pain, is proud to announce one of their physicians has been invited to be ... Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. ...
(Date:4/29/2016)... ON (PRWEB) , ... April 29, 2016 , ... ... and the Canadian Celiac Association (CCA), is pleased to announce the launch of ... gluten-free products, nutritional articles, recipes, and more. The purpose of the GFCP ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):